Pfizers Biosimilar ABRILADA

Pfizer’s Biosimilar ABRILADA Now Available in Canada

eAwaz Medicine

Kirkland – Pfizer is proud to announce that ABRILADA™ (adalimumab), a biosimilar to the reference biologic drug Humira1 (adalimumab), is now available in Canada for the treatment of certain patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease (in people aged 13 and older), ulcerative colitis, plaque psoriasis, uveitis (in adults and children) and hidradenitis suppurativa …